AstraZeneca US Broadens Income Eligibility for Prescription Savings Programs

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (NYSE:AZN) announced today that it broadened the income eligibility for its AZ&Me™ Prescription Savings programs to enable more people to qualify for free medicines.

The new annual household income eligibility levels are $35,000 for individuals, $48,000 for couples, $60,000 for a family of three and $70,000 for a family of four.

Those with an annual household income that falls within the new income eligibility guidelines may receive AstraZeneca medicines for free if they meet all program criteria.

"We made this change to keep pace with the increased cost of living for patients and to ensure they have access to medicines they need,” said Jennifer McGovern, Director, AZ&Me Prescription Savings Programs.

Previously, AstraZeneca provided prescription savings benefits to qualified patients with a total yearly income of $30,000 for individuals, $40,000 for couples, $50,000 for a family of three and $60,000 for a family of four.

In 2010, AstraZeneca also expanded its prescription savings program to provide assistance to those with extenuating circumstances such as those who recently lost their jobs, had their incomes reduced, experienced a change in marital status or had a change in family size. Those who submit documentation showing the change in status may qualify for the program.

AstraZeneca has offered prescription savings programs for 34 years and offers one of the industry’s most generous programs. The company will continue to make program enhancements that better serve patients and the advocates who help them.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information about AstraZeneca in the U.S. or our AZ&Me™ Prescription Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363).



CONTACT:

AstraZeneca
Tony Jewell, 302-885-4594

KEYWORDS:   United States  North America  Delaware

INDUSTRY KEYWORDS:   Seniors  Health  Biotechnology  Pharmaceutical  Philanthropy  Professional Services  Insurance  Other Philanthropy  Consumer  Family  General Health

MEDIA:

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.